Principal Investigator/Program Director (Last, First, Middle) LESCANO, Andres G.

US DoD-AFHSC/GEIS CO533\_12\_L1 (PI) 10/01/2011 to 09/30/2012 0.6 months Malaria infection in human - baited mosquito collectors in Peru $34,000 This study evaluates the risk of vector-borne illnesses among human landing catchers and other entomology personnel in Peru NAMRU-6 IRB: NAMRU6.2012.0017, Mar-08-2012

US DoD-AFHSC/GEIS CO697\_12\_L1 (Investigator) 10/01/2011 to 09/30/2012 0.6 months Latin American Malaria Diagnostics Center $130,000 This project will develop a training center for malaria diagnostics using microscopy following the standard methodology developed by USAMRU-K en Kisumu, Kenya. NAMRU-6 IRB: NAMRU6.2012.0017, Nov-15-2011

US DoD-AFHSC/GEIS CO720\_12\_L1 (Investigator) 10/01/2011 to 09/30/2012 0.6 months Artesunate Resistance in Plasmodium falciparum in Latin America $250,000 This clinical trial will evaluate in-vivo the parasite clearance time of Plasmodium falciparum to artesunate monotherapy in Iquitos, Peru, by delaying two days the delivery of mefloquine in mono-infection, non-complicated patients NAMRU-6 IRB: NAMRU6.2012.0008, approval pending

US DoD-AFHSC/GEIS CO747\_12\_L1 (PI) 10/01/2011 to 09/30/2012 0.6 months Remote riverine surveillance and pathogen discovery in Peru $95,000 This project will implement surveillance capacities in remote riverine settings normally not accessible NAMRU-6 IRB: NAMRU6.2012.0005, Nov-14-2011

US DoD-AFHSC/GEIS CO752\_12\_L1 (Investigator) 10/01/2011 to 09/30/2012 0.6 months Efficacy/Tolerability of a High-dose Primaquine Regimen for Preventing Vivax Relapses in the Peruvian Amazon $194,000 This single arm, open label clinical trial will assess the in-vivo efficacy of an enhanced primaquine dose (50% higher) to prevent Plasmodium vivax malaria relapses due to in Loreto, Peru NAMRU-6 IRB: NAMRU6.2012.0009, approval pending

US DoD-AFHSC/GEIS CO755\_12\_L1 (co-PI) 10/01/2010 to 09/30/2012 0.6 months Comprehensive Leishmaniasis Surveillance in the Peruvian Army $285,000 This study evaluates the incidence of leishmaniasis and risk factors among Peruvian Army personnel deployed to the Apurimac and Ene River Valleys NAMRU-6 IRB: NAMRU6.2011.0013, Mar-08-2012. UPCH IRB: 57314, Dec-09-2010

US DoD-AFHSC/GEIS CO597\_12\_L1 (Co-PI) 06/01/2010 to 09/30/2012 0.6 months Plasmodium vivax Risk factors for severe malaria in Peru $400,000 This program aims at assessing potential clinical and epidemiological markers associated to the etiology of severe vivax malaria in P. falciparum Peru, especially addressing the role of co-morbidities and co-infection. NAMRU-6 IRB: NAMRU6.2012.0006, Feb-07-2012 PJT.NMRCD.078, Sep-01-2010

US DoD-AFHSC/GEIS CO745\_12\_L1 (PI) 10/01/2003 to 09/30/2012 0.6 months Epidemiological Training in the Americas $649,000 This grant aims at developing epidemiological research and response capacity in the Americas, mainly within Ministries of Health No IRB required, this is a training grant

US DoD-GEIS GLI-0026-06-RC (PI) 10/01/2003 to 09/30/2012 0.6 months Epidemiological Training in the Americas $729,000 This grant aims at developing epidemiological research and response capacity in the Americas, mainly within Ministries of Health No IRB required, this is a training grant

NIH/NIAD R01 1P50AI074285-01 (Biostatistician) 10/01/2007 to 31/09/2012 0.6 months

Innovative Approaches to Chagas Disease Diagnosis and Control (Peru TMRC) $667,545 To apply new tools and information in a concerned manner to develop new diagnostic and control methods for Chagas disease which could be applied worldwide. No IRB required, only consultant services were provided

US DoD - SOUTHCOMM (PI) 08/01/2008 to 31/09/2011 0.6 months

Alto Amazonas Comprehensive Health Assessment $340,000 This program will evaluate the impact of successive humanitarian assistance interventions in Alto Amazonas, Peru NAMRU-6 IRB: NMRCD.2009.0002, Dec 27, 2011

US DoD-AFHSC/GEIS CO497\_11\_L1 (PI) 10/01/2010 to 09/30/2011 0.6 months Plasmodium Vivax malaria incidence in infants, children and adults in Northwestern Peru $150,000 This study evaluates the incidence of vivax malaria in different age groups, assessing the role of immunity and asymptomatic infection in middle/low endemic settings.

PHS 398/2590 (Rev. 06/09) Page Biographical Sketch Format Page